US Stock Insider Trading | Maze Therapeutics disclosed 4 insider transactions on February 2

K-LinePoet · 2026-02-04T00:26:20+00:00

Maze Therapeutics disclosed internal trading activities of executive Dandekar Atul in 2026, including the purchase of 7,500 shares and multiple sell transactions. The company focuses on developing small molecule precision medicines for kidney and cardiovascular diseases.

K-LinePoet

2026-02-04 00:26:20

Abstract generation in progress

On February 2, 2026, Maze Therapeutics (MAZE) disclosed four insider transactions. Executive Dandekar Atul purchased 7,500 shares on January 29, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Dandekar Atul	January 29, 2026	Sell	1,200	43.18	$51,800
February 2, 2026	Executive	Dandekar Atul	January 29, 2026	Sell	2,800	45.01	$126,000
February 2, 2026	Executive	Dandekar Atul	January 29, 2026	Buy	7,500	10.42	$78,200
February 2, 2026	Executive	Dandekar Atul	January 29, 2026	Sell	3,500	44.04	$154,100
January 26, 2026	Executive	Bachrodt Amy	January 22, 2026	Sell	5,000	45.52	$227,600
January 26, 2026	Executive	Bachrodt Amy	January 22, 2026	Buy	5,000	10.42	$52,100
January 9, 2026	Executive	Bernstein Harold	January 7, 2026	Sell	25,200	40.20	$1,011,300
January 9, 2026	Executive	Bernstein Harold	January 7, 2026	Buy	25,200	10.42	$262,100
January 8, 2026	Director	Sohn Catherine A.	January 6, 2026	Sell	2,493	38.62	$96,300
January 8, 2026	Director	Sohn Catherine A.	January 7, 2026	Buy	29,400	10.42	$306,500

【Company Information】

Maze Therapeutics, Inc. was incorporated on August 29, 2017, under Delaware law. The company is a clinical-stage biopharmaceutical company leveraging human genetics to develop novel small-molecule precision medicines for patients with kidney, cardiovascular, and related metabolic or CVRM diseases, including obesity. The company is advancing pipelines using their Compass platform, which enables the identification and characterization of genetic variants in diseases, then linking these variants to biological pathways driving disease in specific patient groups through a process called variant functionalization. Their Compass platform is designed to inform all stages of drug discovery and development through clinical trial design. The company is currently advancing two wholly owned lead programs, MZE829 and MZE782, each representing a new precision medicine approach for chronic kidney disease (CKD).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.